Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAPDH | P04406 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | NADK | O95544 | 1/20 | 0.45 |
| ▸ | TRPM2 | O94759 | 5/20 | 0.42 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.40 |
| ▸ | AMD1 | P17707 | 3/20 | 0.39 |
| ▸ | HSPA5 | P11021 | 4/20 | 0.37 |
| ▸ | HSPA8 | P11142 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1098546 | 0.92 | GAPDH (0.55) | GAPDHHSD17B10SIRT2SIRT1NADK | |
| SCHEMBL1098133 | 0.90 | GAPDH (0.45) | GAPDHHSD17B10SIRT2SIRT1NADK | |
| SCHEMBL1096847 | 0.89 | TRPM2 (0.52) | GAPDHHSD17B10SIRT2SIRT1NADK | |
| SCHEMBL1096911 | 0.87 | AMD1 (0.49) | HSD17B10AMD1HSPA5HSPA8RXFP1 | |
| SCHEMBL1135253 | 0.87 | AMD1 (0.49) | HSD17B10AMD1HSPA5HSPA8RXFP1 | |
| SCHEMBL1096954 | 0.85 | ADORA3 (0.48) | GAPDHHSD17B10SIRT2SIRT1NADK | |
| SCHEMBL1096598 | 0.84 | NADK (0.50) | NADKAMD1HSPA5HSPA8RXFP1 | |
| SCHEMBL1106678 | 0.84 | NADK (0.50) | NADKAMD1HSPA5HSPA8RXFP1 | |
| SCHEMBL7254210 | 0.80 | TRPM2 (0.47) | GAPDHHSD17B10SIRT2SIRT1NADK | |
| SCHEMBL7258766 | 0.79 | SIRT2 (0.53) | GAPDHHSD17B10SIRT2SIRT1NADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765844-B1 | PURINE NUCLEOTIDE DERIVATIVES | SOLVELL AS (NO) | 2014-07-30 | — | — | EP | disclosed |
| US-8153609-B2 | Purine nucleotide derivatives | LAURAS AS (NO) | 2012-04-10 | — | — | US | disclosed |
| US-20080293665-A1 | Purine Nucleotide Derivatives | LAURAS AS (NO) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293665-A1 | Purine Nucleotide Derivatives | CGAS, PDE8A, PDE7A | GAPDH 1967/4885HSD17B10 4521/4885SIRT2 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.